AIkido Pharma Inc. (Nasdaq: AIKI) announced progress in its antiviral platform utilizing machine learning in collaboration with the University of Maryland Baltimore. The project aims to identify compounds targeting the SKI complex to inhibit viral replication. SilcsBio LLC employs physics-based machine learning to accelerate the discovery of broad-spectrum antivirals effective against SARS-CoV-2 and other viruses. The ongoing efforts involve optimizing drug candidates for eventual clinical trials, addressing potential future pandemics.
AIkido Pharma Inc. (Nasdaq: AIKI) announced a Notice of Allowance from the U.S. Patent and Trademark Office for its application regarding central nervous system (CNS) homing peptides. This technology, sublicensed for psilocybin use, aims to treat neuroinflammatory diseases in cancer patients. Psilocybin may help alleviate symptoms caused by cancer cachexia. CEO Anthony Hayes emphasized the importance of addressing the psychological impacts of cancer, viewing this development as a significant step for the company.
AIkido Pharma Inc. (Nasdaq: AIKI) provided an update on its antiviral platform in collaboration with the University of Maryland School of Medicine. The project aims to identify compounds that inhibit viral replication targeting a protein complex that degrades RNA. Scientists have identified four lead compounds effective against Influenza, Coronavirus (CoV-2), and Ebolavirus. AIkido's CEO, Anthony Hayes, emphasized the next phase will optimize these compounds, focusing on their bioavailability. The company sees these antiviral efforts as addressing significant unmet medical needs and presenting market opportunities.
AIkido Pharma Inc. (Nasdaq: AIKI) will participate in the Alzheimer's Association International Conference (AAIC 2021) in Denver from July 26-30, 2021. The AAIC is a key event in dementia science, gathering leading researchers and clinicians to discuss advancements in prevention, treatment, and diagnosis of Alzheimer's disease. CEO Anthony Hayes emphasized the importance of addressing unmet medical needs in dementia. AIkido Pharma is known for its diverse portfolio in small-molecule anti-cancer therapeutics and is expanding its focus on innovative drug platforms.
AIkido Pharma Inc. (Nasdaq: AIKI) has filed a provisional patent application for the combination of ketamine and peptides to treat Alzheimer's disease. This follows the company's acquisition of patent rights for peptide drug delivery systems. Alzheimer's, a neurodegenerative disorder, requires effective treatment methods, and AIkido's approach aims to enhance drug delivery to affected cells. The company focuses on innovative therapeutics in oncology and antiviral platforms in addition to this new application.
AIkido Pharma Inc. (Nasdaq: AIKI) announced positive Phase 1 testing data for the antibody 225Ac-J591 at the 2021 ASCO Annual Meeting on June 4, 2021. Key findings highlighted include declining PSA levels and circulating tumor cell (CTC) counts in treated patients, demonstrating good tolerability and preliminary efficacy in a heavily pre-treated population. The Phase 2 trial is currently underway, aiming to further evaluate the drug's potential. The promising results suggest that 225Ac-J591 may enhance existing treatment strategies for advanced prostate cancer.
AIkido Pharma Inc. (Nasdaq: AIKI) announced that Phase 1 testing data will be presented at the 2021 ASCO Annual Meeting on June 4, 2021. The study focuses on 225Ac-J591 for men with metastatic castration-resistant prostate cancer. Renowned physician Dr. Scott Tagawa will present the findings, which indicate that the therapy is tolerable with early signs of clinical activity. A follow-up study is already underway, further exploring therapeutic potential. AIkido continues to advance its pipeline of innovative cancer treatments while pursuing antiviral platforms targeting multiple viruses.
AIkido Pharma Inc. (Nasdaq: AIKI) announced its participation in several upcoming investor conferences. The Company will present at the Benzinga Global SmallCap Conference on May 13, 2021, the Investor Summit Group's Q2 Virtual Summit from May 17-19, 2021, and the LD Micro Invitational XI from June 8-10, 2021. AIkido will showcase an updated investor presentation and discuss its innovative therapeutics targeting unmet needs in oncology. The presentation will be made by Darrell Dotson, Vice President and General Counsel.
AIkido Pharma Inc. (Nasdaq: AIKI) reported its financial results for Q1 2021, showcasing its strongest balance sheet with approximately $102 million in cash. The company is advancing its pipeline, focusing on anti-viral compounds targeting influenza and SARS-CoV-2. Notable projects include a partnership for prostate cancer treatment with Convergent Therapeutics Inc., psychedelic research for PTSD at Mount Sinai, and a patent agreement with Silo Pharma for psilocybin research. AIkido is well-positioned for future growth while maintaining a low cash burn strategy.
AIkido Pharma Inc. (Nasdaq: AIKI) announced Dr. Rachel Yehuda's participation in a panel discussion at SXSW, focusing on the role of psilocybin in mental health care. The discussion highlighted ongoing clinical trials and the potential of psilocybin therapy, recognized as "breakthrough therapy" by the FDA, to address mental health issues such as PTSD and depression, affecting 45 million Americans. AIkido supports this research, aligning with its focus on innovative treatments for psychiatric disorders and oncology.